Prostate cancer is one of the most common malignant tumors in men worldwide, and robot-assisted radical prostatectomy (RARP) has become an important means of treatment. However, postoperative stress urinary incontinence (SUI) is a common complication that seriously affects the quality of life of patients. Data show that 66% to 80% of men continue to have urinary incontinence within 3 months after surgery, and 5% to 20% of patients develop chronic urinary incontinence.

Clinical Challenges of Urinary Incontinence after Prostatectomy
After RARP, the urethra shortens and the bladder neck widens, which puts greater pressure on the urethral sphincter and impairs urinary control. Although current drug treatments can relieve symptoms, it is difficult to fundamentally solve the problem at the anatomical level. There are also problems such as side effects and low patient compliance.

Voro® Urinary Stent – The First Absorbable Postoperative Urinary Control Support Solution
The Voro® Urinary Stent launched by Levee Medical is a bioabsorbable implant designed for urinary incontinence after prostatectomy. Its core principle is to **reduce the pressure on the urethral sphincter and promote urinary control recovery by maintaining urethral length and optimizing the geometry of the bladder neck**.

Working mechanism of Voro® Urinary Stent
Intraoperative implantation: During prostatectomy, the Voro® stent is placed in the urethral stump in a compressed state, then unfolded and positioned at the anastomosis site to form a support structure.
Stent provides support: The stent can optimize the bladder neck morphology, reduce urethral sphincter pressure, and create conditions for the recovery of urinary control function.
Bioresorbable: The stent is made of polydioxanone (PDS) material and is completely absorbed within 180 to 210 days, ensuring the formation of durable connective tissue at the anastomosis site and restoring the urethral structure.

Core advantages of Voro® Urinary Stent
✅ Structural intervention: Compared with drugs, the Voro® stent can directly act on the urethra and bladder neck structure to reduce the incidence of urinary incontinence.
✅ Reduce side effects: The stent can be naturally absorbed by the human body after completing the support task, without the adverse reactions caused by long-term drugs.
✅ Improve compliance: One implant can play a long-term role, and patients do not need to take long-term medication, reducing the burden of treatment management.

Industry impact and future prospects
As the first absorbable stent for urinary incontinence after prostatectomy, the Voro® Urological Stent fills the technical gap in this field. With the advancement of clinical applications, this product is expected to become a new standard for the management of urinary incontinence after prostate cancer surgery, bringing better treatment experience to patients around the world.